ArticleBlood2024

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.

Matthew J Frigault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.